As on Thursday, Kairos Pharma Ltd (AMEX: KAPA) got off with the flyer as it spiked 9.35% to $0.69, before settling in for the price of $0.63 at the close. Taking a more long-term approach, KAPA posted a 52-week range of $0.40-$4.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been -23.37% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was -23.37%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 7.25%. This publicly-traded company’s shares outstanding now amounts to $15.83 million, simultaneously with a float of $7.12 million. The organization now has a market capitalization sitting at $11.63 million. At the time of writing, stock’s 50-day Moving Average stood at $0.6768.
Kairos Pharma Ltd (KAPA) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Kairos Pharma Ltd’s current insider ownership accounts for 57.73%, in contrast to 9.36% institutional ownership. According to the most recent insider trade that took place on Nov 25 ’24, this organization’s VP of Research and Development bought 200 shares at the rate of 1.59, making the entire transaction reach 318 in total value, affecting insider ownership by 133,057. Preceding that transaction, on Nov 22 ’24, Company’s Chief Financial Officer bought 2,500 for 1.50, making the whole transaction’s value amount to 3,750. This particular insider is now the holder of 60,796 in total.
Kairos Pharma Ltd (KAPA) Earnings and Revenue Records
Kairos Pharma Ltd’s EPS increase for this current 12-month fiscal period is 7.25% and is forecasted to reach -0.34 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -24.45% through the next 5 years, which can be compared against the -23.37% growth it accomplished over the previous five years trading on the market.
Kairos Pharma Ltd (AMEX: KAPA) Trading Performance Indicators
Let’s observe the current performance indicators for Kairos Pharma Ltd (KAPA). It’s Quick Ratio in the last reported quarter now stands at 7.52.
In the same vein, KAPA’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.25, a figure that is expected to reach -0.05 in the next quarter, and analysts are predicting that it will be -0.34 at the market close of one year from today.
Technical Analysis of Kairos Pharma Ltd (KAPA)
Through scrutinizing the latest numbers posted by the [Kairos Pharma Ltd, KAPA], it can be observed that its last 5-days Average volume of 0.86 million was lower the volume of 1.61 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 82.12% While, its Average True Range was 0.0760.
Raw Stochastic average of Kairos Pharma Ltd (KAPA) in the period of the previous 100 days is set at 19.08%, which indicates a major fall in contrast to 95.98% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 127.60% that was higher than 105.71% volatility it exhibited in the past 100-days period.
